Transdermal clonidine for ameliorating tamoxifen-induced hot flashes

Richard M. Goldberg, Charles L. Loprinzi, Judith R. O'Fallon, Michael H. Veeder, Angela W. Miser, James A. Mailliard, John C. Michalak, Ann Marie Dose, Kendrith M Rowland, Nora L. Burnham

Research output: Contribution to journalArticle


Purpose: To determine the efficacy of transdermal clonidine for alleviating tamoxifen-induced hot flashes in women with a history of breast cancer. Patients and Methods: A randomized, double-blind, crossover design was used in this prospective study. Women with a history of breast cancer who were receiving tamoxifen and suffering from hot flashes were potentially eligible for this protocol study. Results: Clonidine did reduce hot-flash frequency to a degree that was statistically impressive (P < .0001), but clinically moderate (20% reduction from baseline). It also decreased hot- flash severity (P = .02, 10% reduction from baseline). Clonidine was related to increased mouth dryness (P < .001), constipation (P < .02), itchiness under the patch (P < .01), and drowsiness (P < .05). Conclusion: Better means are needed to alleviate hot flashes among patients in whom estrogen therapy is contraindicated.

Original languageEnglish (US)
Pages (from-to)155-158
Number of pages4
JournalJournal of Clinical Oncology
Issue number1
StatePublished - Jan 1994
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Transdermal clonidine for ameliorating tamoxifen-induced hot flashes'. Together they form a unique fingerprint.

  • Cite this

    Goldberg, R. M., Loprinzi, C. L., O'Fallon, J. R., Veeder, M. H., Miser, A. W., Mailliard, J. A., Michalak, J. C., Dose, A. M., Rowland, K. M., & Burnham, N. L. (1994). Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. Journal of Clinical Oncology, 12(1), 155-158.